"Eye-Black" Sign Secondary to Nivolumab Immunotherapy.

Overview of attention for article published in Clinical Nuclear Medicine, December 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (76th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,041 followers.

Current Issue: “Eye-Black” Sign Secondary to Nivolumab Immunotherapy https://t.co/6qOa91i07o

"Eye-Black" Sign Secondary to Nivolumab Immunotherapy. https://t.co/ssohWMlqQ8

New article: "Eye-Black" Sign Secondary to Nivolumab Immunotherapy. https://t.co/OkPOreYnxr #melanoma #oncology

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.